Latham & Watkins advises Revolution Medicines on the deal, and Goodwin Procter advises EQRx. Revolution Medicines, Inc. (Nasdaq: RVMD) and EQRx, Inc. (Nasdaq: EQRX) announced a definitive agreement...
You must be a Standard 1 Year member to access this content.
Goodwin advised Education Growth Partners on its investment. Uwill announced it has completed a $30 million Series A funding round. The investment further cements Boston-based Uwill...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Bregal Sagemount on the deal. Bregal Sagemount announced its strategic investment in DentalXChange. Together the firms are eyeing robust strategic growth led by a...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Bio Products Laboratory and Tiancheng International Investment Limited on the deal. The shareholders of Kedrion was advised by Carnelutti and Pedersoli Studio Legale,...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Aura Biosciences on the deal. Aura Biosciences, Inc. (Nasdaq: AURA) announced its initial public offering of 5,400,000 shares of common stock at a public...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised EQRx on the deal while White & Case LLP advised CM Life Sciences III Inc. EQRx, Inc. announced its definitive merger agreement with CM...
You must be a Standard 1 Year member to access this content.
Goodwin Procter and Baker McKenzie advised Trillium Therapeutics on the deal, while Ropes & Gray LLP and Norton Rose Fulbright Canada represented Pfizer. Trillium Therapeutics (NASDAQ/TSX:...
You must be a Standard 1 Year member to access this content.
Goodwin Procter LLP and JunHe advised Goldman Sachs & Co. LLC and the other underwriters on the deal, while Wilson Sonsini Goodrich & Rosati and Maples...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised the underwriters on the deal, while Dechert advised Femasys. Chardan, a global investment bank, announced that it acted as lead left bookrunner in...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati and Goodwin Procter LLP advised Centessa Pharmaceuticals on the deal. Centessa Pharmaceuticals, a clinical-stage company employing its innovative asset-centric business model...
You must be a Standard 1 Year member to access this content.
